공시 • Dec 19
TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.2 million. TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.2 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 87,274,663
Price\Range: AUD 0.008
Discount Per Security: AUD 0.00048
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 437,725,337
Price\Range: AUD 0.008
Discount Per Security: AUD 0.00048
Transaction Features: Subsequent Direct Listing 공시 • Oct 27
TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 0.698197 million. TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 0.698197 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 87,274,663
Price\Range: AUD 0.008
Discount Per Security: AUD 0.00048
Transaction Features: Subsequent Direct Listing 공시 • Oct 16
TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 0.698197 million. TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 0.698197 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 87,274,663
Price\Range: AUD 0.008
Discount Per Security: AUD 0.00048
Transaction Features: Subsequent Direct Listing 공시 • Sep 26
TrivarX Limited, Annual General Meeting, Nov 21, 2025 TrivarX Limited, Annual General Meeting, Nov 21, 2025. Location: at the companys registered office, at 647 beaufort street, mount lawley, Australia 공시 • May 20
TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 2.25 million. TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 2.25 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 102,818,898
Price\Range: AUD 0.015
Discount Per Security: AUD 0.0009
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 47,181,102
Price\Range: AUD 0.015
Discount Per Security: AUD 0.0009
Transaction Features: Subsequent Direct Listing 공시 • Mar 17
TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.25 million. TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.25 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 102,818,898
Price\Range: AUD 0.015
Discount Per Security: AUD 0.0009
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 47,181,102
Price\Range: AUD 0.015
Discount Per Security: AUD 0.0009
Transaction Features: Subsequent Direct Listing 공시 • Oct 09
TrivarX Limited, Annual General Meeting, Nov 28, 2024 TrivarX Limited, Annual General Meeting, Nov 28, 2024. Location: 647 beaufort street, mount lawley, western australia., western australia. Australia 공시 • Sep 25
TrivarX Limited Appoints John H. Mathias II as Non-Executive Director, Effective 1 October 2024 TrivarX Limited announced that it has strengthened the composition of its Board with the appointment of Mr. John H. Mathias II as a Non-executive Director, effective 1 October 2024. Mr. Mathias is an accomplished healthcare focused operations and business development executive, with a clinical background in respiratory care. He has a demonstrated track record of success over a 30-year career in the US healthcare industry. Currently, he holds the role of Chief Development Officer at Medbridge Healthcare. MedBridge also has a number of professional partnerships that support adjacent services including hospital readmission reduction programs (HRRP), product and drug research, occupational health, professional services and therapeutic sleep offerings. As CDO, he plays a central role in building partnerships with stakeholders across the US healthcare system in the field of sleep medicine including hospitals, medical research institutions, clinical partnerships, and insurance companies. Prior to his role as CDO, Mr. Mathias also served as Chief Operating Officer and President of Sleep Services of America Inc., an entity of Johns Hopkins Health System, where he managed operations for sleep diagnostics and therapeutic coordination, oversaw strategic M&A and led a business turnaround which returned the division to profitability. Throughout his career, Mr. Mathias has been recognised for building and leading high-performing healthcare managers and sales teams and implementing strategic business plans to drive consistent growth in revenue and margin levels. With direct experience across several US healthcare industries, his core areas of expertise include contract management services for sleep and respiratory services, along with acute care hospital operations and developing improved patient solutions in the aged care industry. Mr. Mathias' appointment provides the Board with additional depth and expertise as it moves from clinical development towards regulatory approval and commercialisation for its proprietary MEB-001 algorithm with the effective screening of a current Major Depressive Episode (cMDE) in the US market. 공시 • May 02
TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 70,970,745
Price\Range: AUD 0.025
Discount Per Security: AUD 0.0015
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 29,029,255
Price\Range: AUD 0.025
Discount Per Security: AUD 0.0015
Transaction Features: Subsequent Direct Listing 공시 • Oct 06
Medibio Limited, Annual General Meeting, Nov 29, 2023 Medibio Limited, Annual General Meeting, Nov 29, 2023, at 09:00 W. Australia Standard Time. Location: COMO The Treasury, Executive Boardroom, 1 Cathedral Avenue, Perth WA 6000 Australia 공시 • Feb 18
Medibio Limited Appoints Christopher Ntoumenopoulos as Director Medibio Limited announced the appointment of Christopher Ntoumenopoulos as Director of the company. The date of appointment is 15 February 2023. 